Skip to main content
. 2013 Jul 9;8(7):e68973. doi: 10.1371/journal.pone.0068973

Figure 3. PCI-24781 regulates AKT mRNA levels.

Figure 3

(A) Basal levels of AKT1, 2, and 3 mRNA in MCF7 cells are presented relative to AKT1 expression. (B) AKT1 and 2 mRNA expression was determined in MCF7 cells following treatment with increasing concentrations of PCI-24781 for 24 hours. (C) MCF7 cells were treated with 0.1 µM PCI-24781 (P), 5 µg/mL actinomycin D (Actino D), or the combination (P+Actino D) and evaluated for AKT1 mRNA expression after 0, 12, 24, and 48 hours treatment. (D) MCF7 cells were pretreated with vehicle or 10 µg/mL cycloheximide for 1 hour. Vehicle and cycloheximide pretreated cells were then each divided and treated with vehicle (V) or 0.1 µM PCI-24781 (P) with or without 10 µg/mL cycloheximide (CycloH) for 24 hours and evaluated for AKT1 mRNA expression. (E) MCF7 cells were treated with vehicle, 0.1 µM PCI-24781, 3 mM valproic acid (VPA), or 30 nM trichostatin A (TSA) for 24 hours and evaluated for AKT1 mRNA expression. All treatments were conducted in triplicate and expressed as the average with the error bars indicating the standard error of the mean. An (*) indicates a significant difference (P-value < 0.05) and a (#) an insignificant difference (P-value > 0.05) compared to vehicle or zero time treatment.